Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead Sciences’ “Zeroing In” program helps 116 grantees boost HIV innovation, education and outreach in marginalized communities.
COVID-19 had an “immense impact” on HIV, hepatitis and STI screening, prevention and care.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
PrEP taken before and after sex, instead of daily dosing, has been found to be highly effective.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
Lessons learned from HIV have informed the response to COVID-19, but has the new focus derailed HIV services?
Plus: Buy a “Queer Blood America” work by artist Jordan Eagles, who fights the FDA’s discriminatory ban on blood donors.
COVID-19 has led to increased use of telemedicine, but it’s not suited for all patients or all situations.
Experts discuss the topic, and Amida Care recommends solutions. Plus: It’s PrEP Aware Week in the Empire State.
Studies of the link between tenofovir use and coronavirus infection or COVID-19 outcomes have yielded mixed results.
At My House Clinic, which also offers hep C and COVID-19 services, PRIDE stands for “Promotes Respect Inclusion & Dignity for Everyone.”
However, PrEP still remains widely available, often provided via telemedicine.
Experts offer advice about how to stop and restart PrEP in the era of social distancing.
A survey of local health departments reveals concerning news—and a silver lining.
As a result, researchers in Spain are testing whether HIV med Truvada, often used as PrEP, can also prevent COVID-19.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.